Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
20th Anniversary of Marine Drugs
This year marks the 20th anniversary of Marine Drugs (ISSN: 1660-3397). Marine Drugs is a leading, peer-reviewed, open-access journal on the research, development, and production of biologically and therapeutically active compounds from the sea. In the past twenty years, Marine Drugs has collaborated with nearly 900 Academic Editors, 7700 reviewers, and 22,000 authors from all over the world, publishing more than 5600 peer-reviewed papers. We are deeply grateful for the great contributions of our Academic Editors, reviewers, and authors to the development of the journal. To celebrate its 20th anniversary, we are arranging a series of special content and events. We warmly invite you to join us in celebrating this milestone for Marine Drugs and enjoy the collection below.
Development and Achievements
View the 20-year timeline infographic here. Trace the development of Marine Drugs from its origins with remarkable events.
Founding Editor-in-Chief Prof. Dr. Hua-Shi Guan
Prof. Dr. Hua-Shi Guan has been engaged in the development of marine biological resources as well as the teaching and research of marine pharmaceuticals and food engineering. He was elected as an academician of the Chinese Academy of Engineering in 1995. As a marine pharmacologist, Prof. Dr. Guan is one of the most prominent pioneers and founders of marine pharmacological studies in China.
The inaugural issue was released. Marine Drugs was published as a quarterly journal.
Marine Drugs was indexed by Science Citation Index Expanded (SCIE), in the Category “Medicinal Chemistry”.
Editor-in-Chief Prof. Dr. Peter Proksch
Prof. Dr. Peter Proksch is a distinguished and internationally known natural product chemist who devoted most of his professional career studying marine natural products derived from benthic macro-organisms, mainly sponges, molluscs, and tunicates, and from fungi as well. His research interests focus on structure elucidation and the mode of action of new bioactive metabolites with potential application in pharmaceutical sciences and in agriculture, on chemical ecology, and the natural functions of secondary metabolites as well as on co-cultivation techniques to activate silent biogenetic gene clusters of microorganisms to biosynthesize novel bioactive metabolites.
Marine Drugs was indexed by PubMed.
Editor-in-Chief Prof. Dr. Hartmut Laatsch
Prof. Dr. Hartmut Laatsch is a distinguished and internationally known scientist in marine natural product studies, with outstanding achievements in the isolation, pure preparation, and structure analysis of pharmacologically relevant natural products from plants and microorganisms, and in the development of natural products databases.
Marine Drugs adopted a monthly publication schedule.
Marine Drugs was indexed by Scopus, in the Category “Drug Discovery”.
Editor-in-Chief Prof. Dr. Alejandro M. Mayer
Prof. Dr. Alejandro M. Mayer is a distinguished and internationally known marine pharmacologist at the Pharmacology Department, College of Graduate Studies, Midwestern University. His research interests include the immunopharmacology and immunotoxicology of marine natural products and writing comprehensive preclinical marine pharmacology annual reviews since 1998. Prof. Dr. Mayer has served as the President of the Great Lakes Chapter of the American Society for Pharmacology and Experimental Therapeutics (2011–2013), is a member of the Natural Products Section, International Union of Basic and Clinical Pharmacology, and initiated the marine pharmacology/pharmaceutical pipeline website in 1998, which is currently available at www.marinepharmacology.org.
Editor-in-Chief Prof. Dr. Orazio Taglialatela-Scafati
Prof. Dr. Orazio Taglialatela-Scafati is a distinguished and internationally known scientist in natural product research. His scientific interests focus on the isolation, structural characterization, and semisynthetic modification of metabolites from both marine invertebrates and terrestrial plants to be applied as lead compounds in drug discovery or as tools to investigate the mode of actions and biochemistry.
Marine Drugs became an affiliated journal of The Australia New Zealand Marine Biotechnology Society (ANZMBS).
Marine Drugs was indexed by a new Category, “Pharmacology & Pharmacy”, in Web of Science–Journal Citation Report.
Marine Drugs was indexed by two new Categories, “Pharmaceutical Science” and “Pharmacology, Toxicology and Pharmaceutics (miscellaneous)”, in Scopus.
Editor-in-Chief Prof. Dr. Bill J. Baker
Prof. Dr. Bill J. Baker is a distinguished and internationally known scientist in the studies of marine invertebrates and algae from Antarctica and deep-sea invertebrates from the Irish continental margin. He currently maintains a laboratory at the University of South Florida that focuses on chemical ecology, drug discovery, and biosynthesis. His research is highly collaborative, involving colleagues with expertise in field work, ecology, systematics, pharmacology, biochemistry, microbiology, and molecular biology, among others.
The journal established eight new sections:
- Structural Studies on Marine Natural Products;
- Marine Pharmacology;
- Marine Toxins;
- Biomaterials of Marine Origin;
- Marine Biotechnology Related to Drug Discovery or Production;
- Synthesis and Medicinal Chemistry of Marine Natural Products;
- Marine-Derived Ingredients for Drugs, Cosmeceuticals and Nutraceuticals;
- Marine Chemoecology for Drug Discovery.
Twitter and LinkedIn
Visit Twitter and LinkedIn using #MarineDrugs20th to share your story with Marine Drugs.
Marine Drugs 2023 Travel Award
We are pleased to announce the Marine Drugs 2023 Travel Award. This award provides CHF 1000 to one junior scientist to attend an international conference relevant to the Marine Drugs journal’s scope, including research, development, and production of biologically and therapeutically active compounds from the sea.